In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

Researchers at UT Southwestern Medical Center found that tenecteplase, a newer drug, is just as safe and effective as ...

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The ...

Since brain damage occurs and progresses rapidly during an acute ischemic stroke, immediate, fast-acting medical care is vital. “Today’s approval is a significant step forward and underscores ...

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The findings suggest that the treatment may work as an add-on therapy to standard ...

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.